Pfizer, Eli Lilly Report Unfavorable FDA Advisory Panel Vote for Tanezumab
March 25 2021 - 4:36PM
Dow Jones News
By Josh Beckerman
Pfizer Inc. and Eli Lilly & Co. announced an unfavorable
vote from a joint U.S. Food and Drug Administration advisory
committee on tanezumab for osteoarthritis pain.
The companies said the vote was one in favor and 19 against on
the question of whether the proposed risk evaluation and mitigation
strategy would ensure benefits outweigh risks.
Pfizer and Lilly said, "While we are disappointed with today's
outcome, we continue to believe that tanezumab has a positive
benefit-risk profile for patients with moderate-to-severe
osteoarthritis pain for whom current treatments are ineffective or
not appropriate."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 25, 2021 16:21 ET (20:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024
